The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global neurorehabilitation devices market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 12% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Neurorehabilitation devices refer to the equipment used for examination of the brain and central nervous system (CNS). Some of the commonly used devices include neurorobotic systems, non-invasive brain stimulators, neuroprosthetics, brain-computer interfaces and wearable devices. These devices assist in the diagnosis and treatment of a disease, disorder or injury in the nervous system of the patient. They facilitate in re-learning motor skills and optimal recovery from neurological disorders, such as Parkinson’s disease, and cardiovascular stroke. As a result, neurorehabilitation devices find extensive applications across various clinics, cognitive care and research institutes and healthcare centers.
The increasing prevalence of neurological diseases, such as multiple sclerosis, Parkinson’s disease and cerebral palsy, is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. Neurorehabilitation devices aid in deploying diversified electric signals to multiple fibers of the spinal cord for the recovery of limb movements. Additionally, various technological advancements, such as the gamification of rehabilitation activities through virtual reality (VR), robotics and artificial intelligence (AI), that aid in promoting recovery are acting as other growth-inducing factors. In line with this, the utilization of novel multi-electrode stimulation for the treatment of spinal cord injuries is also contributing to the market growth. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurorehabilitation devices market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type, application and end user.
Breakup by Product Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc and Tyromotion GmbH.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc and Tyromotion GmbH.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at